Shanghai Pharmaceuticals (SHPMF) Stock Price, News & Analysis

Company Overview

Shanghai Pharmaceuticals Holding Co., Ltd. engages research, development, manufacture, distribution, and retailing of pharmaceutical and healthcare products in China and internationally. The company operates through four segments: Production, Distribution, Retail, and Others. It offers chemicals and biochemicals, Chinese medicines, healthcare products, and medical devices in various therapeutic areas, including digestive system, immune metabolism, motor neuron disease, endocrinology, cardiovascular, psychoneurotic, neoplasm, autoimmunity, systemic anti-infection, mental nerve, anti-tumor, oncology, respiratory system, nervous system, auto-immunity, hypertension, neuromyelitis, diabetes, anticholinesterase, polypeptide hormones uterine tonic, antihistamine, anti-inflammatory, anesthetic, immunomodulatory, antiviral, reflux esophagitis, analgesics, weight management, malignant peritoneal effusion, ulcerative colitis, myasthenia gravis, burn injury, anticoagulant, anti-epileptic, anticonvulsant, Alzheimer's, and inflammatory bowel diseases. The company also engages in the provision of pharmaceutical distribution, warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it engages in the operation of a network of retail pharmacy stores. The company was incorporated in 1994 and is headquartered in Shanghai, China.

Key Stats

• Today's Range: $1.56 to $1.56
• 50-Day Range: $1.56 to $1.57
• 52-Week Range: $0.99 to $1.95
• Volume: N/A
• Average Volume: 33,943 shs
• Market Capitalization: N/A
• P/E Ratio: 1.68
• Dividend Yield: 16.86%
• Price Target: N/A
• Consensus Rating: N/A

Shanghai Pharmaceuticals Stock Analysis - MarketRank™

Shanghai Pharmaceuticals scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Shanghai Pharmaceuticals.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Shanghai Pharmaceuticals is 1.68, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 22.42.

Price to Earnings Ratio vs. Sector

The P/E ratio of Shanghai Pharmaceuticals is 1.68, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 25.18.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Shanghai Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Shanghai Pharmaceuticals has recently increased by 24.81%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Shanghai Pharmaceuticals pays a meaningful dividend of 2.01%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Shanghai Pharmaceuticals does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Shanghai Pharmaceuticals is 28.26%. This payout ratio is at a healthy, sustainable level, below 75%.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Shanghai Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Shanghai Pharmaceuticals has recently increased by 24.81%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Sentiment

Shanghai Pharmaceuticals has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Shanghai Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 6.84% of the stock of Shanghai Pharmaceuticals is held by institutions.

SHPMF Stock Analysis - Frequently Asked Questions

How have SHPMF shares performed this year?

Shanghai Pharmaceuticals' stock was trading at $1.64 at the start of the year. Since then, SHPMF stock has decreased by 4.7% and is now trading at $1.5624.
View the best growth stocks for 2025 here.

How do I buy shares of Shanghai Pharmaceuticals?

Shares of SHPMF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Medical Distribution
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:SHPMF
• CIK: 1570300
• Web: www.sphchina.com
• Phone: 86-21-6373-0908
• Fax: N/A
• Employees: 49,234
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: 1.68
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A